Stans/Switzerland, May 16, 2017 – NLS Pharma Group (NLS Pharma), a Swiss biotech group focusing on the development of novel treatments for ADHD, sleep disorders, and cognitive impairments, announced today that its “Double-Blind Placebo-Controlled Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention Deficit Hyperactivity Disorder (ADHD),” NLS-1001, has met its primary and secondary endpoints.

“The promising results of NLS-1, our lead ADHD compound, in the Phase II study are very encouraging and demonstrate the potential for Mazindol CR (NLS-1) to make a difference in the lives of patients suffering from ADHD across the world,” said Alex Zwyer, CEO of NLS Pharma.

NLS Pharma is investigating NLS-1 as a potential alternative to conventional first-line treatments in ADHD. Drug discovery scientists at NLS Pharma hypothesize that the performance exhibited by NLS-1 in the Phase 2 trial may be explained by the molecule’s unique Mechanism of Action (MoA) in potentially regulating the orexins system in the hypothalamus. The clinical potential of Mazindol to improve ADHD symptoms was first observed in an open label pilot study which assessed the efficacy, safety and pharmacokinetics of mazindol in children with ADHD (MAZDAH study).

NLS Pharma will host exhibit booth #955 at the annual scientific meeting of the American Psychiatric Association (APA) being held May 20–24 at the San Diego Convention Center in San Diego, CA.

About NLS Pharma

NLS Pharma Group (NLS Pharma) is a privately owned, Swiss-based biotech group focusing on the development of first-in-class treatments for attention deficit hyperactivity disorder (ADHD), sleep disorders, cognitive impairment and other neurological disorders that remain largely underdiagnosed and for which unmet medical needs are significant. NLS Pharma has built a large portfolio of promising clinical-stage medicines being developed by an experienced team of proven experts in ADHD and sleep-related disorders and working closely with key opinion leaders.

Media
Jon Siegal, MSLGROUP
Danae McKenzie, MSLGROUP
781-684-0770
nlspharma@mslgroup.com

NLS Pharma Contacts
Alex Zwyer, CEO, az@nls-pharma.com
Hervé Girsault, Head of M&A and Business Development, hg@nls-pharma.com

###